Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
Healthcare
$0.86 -4.70%
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
52W Low $0.84High $5.40
Volume 0.00M
Average 0.00M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$3.83M
FY 2025 · Annual
Investing Cash Flow
$17,000.00
FY 2025 · Annual
Financing Cash Flow
$2.80M
FY 2025 · Annual
-49.2% YoYCash Flow Statement
CAD
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (8.04M) | (6.56M) | (6.29M) | (9.26M) | (5.21M) |
| Depreciation & Amortization | 199K | 12K | 13K | 14K | 10K |
| Deferred Income Tax | (2.22M) | 9K | 0 | 0 | 0 |
| Stock-Based Compensation | 664K | 425K | 570K | 3.52M | 0 |
| Change in Working Capital | (54K) | (892K) | 186K | 485K | 1.33M |
| Accounts Receivables | (173K) | 74K | 217K | 8K | (68K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 50K | (867K) | (106K) | 0 | 0 |
| Other Working Capital | 69K | (99K) | 75K | 477K | 1.4M |
| Other Non-Cash Items | 142K | 500K | (5K) | 31K | 31K |
| Operating Cash Flow | (9.3M) | (6.51M) | (5.53M) | (5.22M) | (3.83M) |
| Capital Expenditures | 0 | 0 | (10K) | (14K) | (2K) |
| Acquisitions (Net) | 2.02M | 0 | 5K | 0 | 19K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.02K | 0 | 5K | 0 | 0 |
| Investing Cash Flow | 2.02M | 0 | (5K) | (14K) | 17K |
| Debt Repayment | 3M | 0 | (2.06M) | 0 | 0 |
| Common Stock Issued | 3.56M | 2.99M | 4.15M | 5.51M | 2.8M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.56M | 3.21M | 999K | 0 | 0 |
| Financing Cash Flow | 6.56M | 6.21M | 3.09M | 5.51M | 2.8M |
| Effect of Forex Changes | 52K | (9K) | 0 | 0 | 0 |
| Net Change in Cash | (670K) | (313K) | (2.44M) | 273K | (1.02M) |
| Free Cash Flow | (9.3M) | (6.51M) | (5.54M) | (5.23M) | (3.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$5.2M
+ D&A$10.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$1.3M
+ Other Non-Cash$31.0K
= Operating Cash Flow-$3.8M
- Capex-$2.0K
= Free Cash Flow-$3.8M
Analysis
FY2025 free cash flow is -$3.8M. FCF conversion is 73.6% of net income. Operating cash flow was -$3.8M, with capex of -$2.0K. The largest bridge item is Working Capital at $1.3M.
Recent Filings
Recent regulatory filings
No filings found.
Does HBP.TO generate free cash flow?
Helix BioPharma Corp. (HBP.TO) generated -$3.83M of free cash flow in fiscal 2025.
How much operating cash flow does HBP.TO produce?
Operating cash flow was -$3.83M, before capital expenditures of $2,000.00.
Continue the stock analysis
Jump to another research area for this company.